Status:
COMPLETED
Intravitreal Bevacizumab for Idiopathic Macular Telangiectasia
Lead Sponsor:
University of Sao Paulo
Collaborating Sponsors:
Coordenação de Aperfeiçoamento de Pessoal de Nível Superior.
Conditions:
Retina
Telangiectasis
Eligibility:
All Genders
40+ years
Phase:
PHASE3
Brief Summary
Idiopathic Macular Telangiectasia is characterized by incompetent and dilated retinal capillaries in the foveolar region of unknown cause for retinal telangiectasia. In Idiopathic Macular Telangiecta...
Eligibility Criteria
Inclusion
- patients with idiopathic macular telangiectasia
- patient consent
Exclusion
- heart attack or cerebrovascular attack
- previous treatment for others retinopathy
- media opacities that preclude visualization of the fundus
- inability to understands the implications of the protocol
Key Trial Info
Start Date :
January 1 2006
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
December 1 2007
Estimated Enrollment :
31 Patients enrolled
Trial Details
Trial ID
NCT00451763
Start Date
January 1 2006
End Date
December 1 2007
Last Update
July 23 2008
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
From the Retina and Vitreous Service, Department of Ophthalmology. Sao Rafael Hospital, Monte Tabor Foudation
Salvador, Estado de Bahia, Brazil, 41253-190